Home page |Editorial  board | About the Journal   | Instructions for Authors | Peer Review Policy | Clinical and Experimental Work Code |   Contact  |

 

Acta Medica Medianae
Vol. 41
No 5, 2002
UDK 61
YU ISSN 0365-4478

 




Contact:
Milica Pešić
Clinicfor Endocrinology, Diabetes and Metabolism Diseases of the Clinic Center, Nis

 

TREATMENT OF THE TYPE 2 OF DIABETES PATIENTS WITH THE

SECONDARY FAILURE OF THE ORAL THERAPY: COMPARISON OF

THE INSULIN-SULFONVLUREA REGIME AND THAT OF THE

INSULIN-METFORMIN

 

Milica Pešić, Dragan Dimić, Slobodan Antić, Saša Živić and Olivera Jovanović

 

Clinicfor Endocrinology, Diabetes and Metabolism Diseases of the Clinic Center, Nis

 

The regime of combined therapies, namely, insulin plus an oral antidiabetics represents a rational alternative to the mono insulin therapy, especially in the group of moderately obese patients with the signs of the secondary failure of the oral therapy There has been the insulin-sulfonylurea therapy applied for many years- however reemergence of metformin in the dialectological practice in the last few years has conditioned an increase of interest in the insulin-metformin combination The research has comprised 37 of the type 2 diabetes patients who were after the secondary failure of the oral therapy was determined, subjected to various regimes of the combined therapy with the purpose of comparing the efficiency of the two regimes, namely, of the insulin-sulfonylurea and the insulin-metformin ones The results clearly show the advantages of the insulin-metformin regime. They primarily refer to the possibility of achieving the same level of glycoregulation with smaller insulin doses. The insulin-metformin combination causes a considerably better muslin prandial profile while it shows smaller advantages regarding the correction of lipid abnormities in the examined patients.

Key words: Type 2 diabetes, combined therapy, insulin, sulfonylurea, metformin